Table 2.
Parameters | TNBC patients (N=179) |
---|---|
Age (years) | 45.9±6.1 |
BMI (kg/m2) | 23.3±2.0 |
Obesity (n/%) | 35 (19.6) |
Smoke (n/%) | 32 (17.9) |
Hypertension (n/%) | 41 (22.9) |
Diabetes mellitus (n/%) | 8 (4.5) |
Dyslipidemia (n/%) | 32 (17.9) |
Hyperuricemia (n/%) | 31 (17.3) |
Chromic kidney disease (n/%) | 4 (2.2) |
Pathological grade (n/%) | |
Grade 1 | 44 (24.6) |
Grade 2 | 117 (65.3) |
Grade 3 | 18 (10.1) |
Tumor size (cm) | 3.0 (2.2-4.0) |
T stage (n/%) | |
T1 | 34 (19.0) |
T2 | 135 (75.4) |
T3 | 10 (5.6) |
N stage (n/%) | |
N0 | 79 (44.1) |
N1 | 68 (38.0) |
N2 | 32 (17.9) |
TNM stage (n/%) | |
II | 145 (81.0) |
III | 34 (19.0) |
ECOG performance (n/%) | |
0 | 138 (77.1) |
1 | 41 (22.9) |
LVEF (%) | 67.0 (64.0-71.0) |
cTnI (ng/mL) | 0.021 (0.010-0.049) |
NT-proBNP (ng/mL) | 0.076 (0.060-0.096) |
Data were presented as the mean ± standard deviation, count (%) or median (25th-75th quantiles). Obesity was defined as BMI ≥25 kg/m2. TNBC, triple-negative breast cancer; BMI, body mass index; ECOG, Eastern Cooperative Oncology Group; LVEF, left ventricular ejection fraction; cTnI, cardiac troponin I; NT-proBNP, N-terminal pro brain natriuretic peptide.